Value
8.8/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 8.6 |
| Analyst target | 9.0 |
- ▸Attractively valued
NVCR · Why this verdict
Why NovoCure (NVCR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
NovoCure generates positive free cash flow despite GAAP losses and has beaten earnings estimates in 3 of the last 4 quarters, but quality metrics remain just below the minimum threshold and analysts project 49% upside that the current technicals do not yet support.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts covering NovoCure project 49% upside to their consensus price target, suggesting institutional models assign significant value to the company's technology pipeline beyond what the current trading price reflects. Sentiment breakdown | The stock price rises above $22 within 12 months as analyst coverage broadens and the pipeline progresses toward key clinical milestones. | →Stable |
| CounterThe analyst coverage is noted as light with only 7 analysts, making the consensus target less reliable as a signal of true market consensus. | ||
NovoCure is free-cash-flow positive with a 1% FCF margin and 0.2% FCF yield even while reporting a GAAP loss, demonstrating that cash generation is more resilient than headline earnings suggest. Quality breakdown | Free cash flow margin improves above 5% within 4 quarters as the company scales its commercial infrastructure without proportional cost increases. | →Stable |
| CounterA 1% FCF margin is extremely thin and the Rule of 40 score of 13 is a failing grade, meaning the combined growth and profitability profile does not yet justify a premium valuation. | ||
NovoCure beat analyst EPS estimates in 3 of the last 4 quarters, with an average positive surprise of 13.6%, indicating the management team is delivering outcomes ahead of consensus expectations. Earnings | EPS surprise remains above 0% in at least 3 of the next 4 quarters, maintaining the beat pattern. | →Stable |
| CounterThe most recent quarter saw a miss of 20.9%, which was the largest deviation in either direction over the period, suggesting recent execution may be inconsistent. | ||
An 11% short interest introduces meaningful downside pressure from bearish market participants who are positioned against the stock, creating a headwind for price appreciation unless positive catalysts emerge. Risk breakdown | Short interest falls below 7% within 12 months as clinical or commercial news reduces bearish conviction. | →Stable |
| Counter11% short interest, while elevated, is not extreme, and can quickly compress on positive trial results, which would act as a tailwind rather than a persistent headwind. | ||
Analysts covering NovoCure project 49% upside to their consensus price target, suggesting institutional models assign significant value to the company's technology pipeline beyond what the current trading price reflects.
→StableSentiment breakdown
- Expectation
- The stock price rises above $22 within 12 months as analyst coverage broadens and the pipeline progresses toward key clinical milestones.
CounterThe analyst coverage is noted as light with only 7 analysts, making the consensus target less reliable as a signal of true market consensus.
NovoCure is free-cash-flow positive with a 1% FCF margin and 0.2% FCF yield even while reporting a GAAP loss, demonstrating that cash generation is more resilient than headline earnings suggest.
→StableQuality breakdown
- Expectation
- Free cash flow margin improves above 5% within 4 quarters as the company scales its commercial infrastructure without proportional cost increases.
CounterA 1% FCF margin is extremely thin and the Rule of 40 score of 13 is a failing grade, meaning the combined growth and profitability profile does not yet justify a premium valuation.
NovoCure beat analyst EPS estimates in 3 of the last 4 quarters, with an average positive surprise of 13.6%, indicating the management team is delivering outcomes ahead of consensus expectations.
→StableEarnings
- Expectation
- EPS surprise remains above 0% in at least 3 of the next 4 quarters, maintaining the beat pattern.
CounterThe most recent quarter saw a miss of 20.9%, which was the largest deviation in either direction over the period, suggesting recent execution may be inconsistent.
An 11% short interest introduces meaningful downside pressure from bearish market participants who are positioned against the stock, creating a headwind for price appreciation unless positive catalysts emerge.
→StableRisk breakdown
- Expectation
- Short interest falls below 7% within 12 months as clinical or commercial news reduces bearish conviction.
Counter11% short interest, while elevated, is not extreme, and can quickly compress on positive trial results, which would act as a tailwind rather than a persistent headwind.
Per-dimension breakdown
Quality
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.7 |
| FCF quality | 3.2 |
| Moat | 6.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 1%, FCF yield 0.3%)
- ▸Rule of 40: 13 (fail)
Growth
5.6/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 5.6 |
Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.2 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.0 |
- ▸Uptrend pullback (RSI 33) - buy opportunity
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.4 |
| Analyst rating | 6.7 |
| Price target | 9.9 |
- ▸Light analyst coverage (7.0) — signal dampened
- ▸Analyst upside: 76%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $939,748 (0.055% of mkt cap)
Peer rank
3.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.7 |
| quality rank | 0.9 |
| growth rank | 6.0 |
Technical
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.0 |
| support resistance | 7.3 |
| 52w position | 4.7 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.7 |
| days to cover | 5.9 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 1.2 |
| max pain risk | 3.0 |
| beta | 7.5 |
| debt equity | 6.7 |
- ▸High IV: 73%
- ▸Above max pain $10
Catalyst
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 9.3 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- ASYMMETRY:3.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST:0.60
- EARNINGS_PROXIMITY:28d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.4<4.5
Warning (0)
none
Reward-to-Risk
3.61
Upside
+53.4%
Downside
14.8%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeCATALYST — Earnings in 28d with 3/4 beat streak
SuitabilityAGGRESSIVE — MCap $1.7B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.8 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:4.4<4.5.
The strongest dimensions are Value at 8.8, Sentiment at 7.2, and Catalyst at 6.8; the weakest are Peer rank at 3.2, Insider at 3.9, and Quality at 3.9. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 3.61 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1NovoCure is free-cash-flow positive with a 1% FCF margin and 0.2% FCF yield even while reporting a GAAP loss, demonstrating that cash generation is more resilient than headline earnings suggest.
Trip ifFree cash flow falls below $0 for 2 consecutive quarters.
- P2NovoCure beat analyst EPS estimates in 3 of the last 4 quarters, with an average positive surprise of 13.6%, indicating the management team is delivering outcomes ahead of consensus expectations.
Trip ifEPS surprise falls below negative 15% in at least 2 of the next 4 quarters.
- P3Analysts covering NovoCure project 49% upside to their consensus price target, suggesting institutional models assign significant value to the company's technology pipeline beyond what the current trading price reflects.
Trip ifAnalyst consensus price target falls below $18, indicating at least 2 target cuts within 12 months.
- P4An 11% short interest introduces meaningful downside pressure from bearish market participants who are positioned against the stock, creating a headwind for price appreciation unless positive catalysts emerge.
Trip ifShort interest rises above 20% of float.